Adjuvants for human vaccines--current status, problems and future prospects.
about
Vaccines for preventing herpes zoster in older adultsUse of licensed vaccines for active immunization of the immunocompromised hostPrototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switchSafety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infantsPlastids: The Green Frontiers for Vaccine ProductionUltrasound-enhanced transdermal delivery: recent advances and future challengesMixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvantsEngineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticlesA novel laser vaccine adjuvant increases the motility of antigen presenting cellsAdjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating.Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.Identification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data.Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.Vaccine technology: looking to the future.Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsEvaluation of mucoadhesive PLGA microparticles for nasal immunization.Humoral immune response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease.An epitope delivery system for use with recombinant mycobacteria.Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregationEvaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virusKinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine.Mucosal adjuvanticity of immunostimulatory DNA sequences.Laser vaccine adjuvant for cutaneous immunization.Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c miceHMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid AVaccine adjuvants: current state and future trends.Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating AgentsA trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.Current state of pneumococcal vaccines.Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice.Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A.Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Study of capsular polysaccharide from Vibrio parahaemolyticus.
P2860
Q24186050-EC09D784-AEE7-434C-A706-42793D2145FBQ24533456-A478CF4D-62E7-4C48-A039-4D045A8135BCQ24676179-D63CC494-E56C-45C0-B022-336A86BCBF1FQ24795590-3FB91B1B-18C6-4DD3-A750-2A7B689E1360Q26774629-5335CCBF-A855-4C99-98DA-27723F5131DBQ26829601-566E7B88-218B-423A-B880-9C1763D5D939Q27304735-706BA60B-B8ED-473D-829C-163AD603D950Q28394668-14404241-E151-4653-B344-9346B45368B8Q28475973-3AEA1201-BB1B-4EF6-B5BE-172E6CE9B541Q30241084-CB70AB99-1EF2-45E7-9A11-D1334D0E1A3DQ30397437-A43A47D7-E72C-42A0-BFC5-9D344D6BC62AQ31054454-60978914-52A3-4C17-9ED4-76C7A2C6F8FEQ33552269-6BD1F718-F4C6-431F-B66C-CFC80D33AA6EQ33603392-A3886B22-AA95-4B4B-B743-20C1EAAC45D5Q33640085-D4F11DFB-936A-4A72-A4BD-30A006976D91Q33646641-24B59F7E-4EAE-4D5C-9C63-E1F0B1C73A06Q33721641-14D4806D-218C-49BF-82F0-2725C211D137Q33749489-BCC43F9E-FC5E-4F73-A42C-EE3AAA95D08BQ33752062-C4770C69-DAFA-40CE-8EBD-3E8369793146Q33757525-06C7BC2B-F577-4407-BCE7-6A2FECC882EEQ33767232-FECD464A-64F7-4971-89F5-74D9F925151BQ33803787-1CDFE446-34C7-4EA7-9123-7F6BFA25AF75Q33992027-E72916BB-7E39-4D44-948A-12E15F013F5CQ34005448-C30759F5-7C62-437F-8DE5-026671C71CDDQ34046148-505DB5A2-5CC0-4688-AB14-D1FAFCFDA488Q34121068-B5A8626C-FC80-41A8-AACB-DA73DAAC3522Q34238526-C75B049B-9F60-4488-9F4C-77E47CB3ADBFQ34258873-B64E322F-EFC1-4B1C-93CE-BD1AC4210510Q34351055-9F5BD417-6C8F-436F-BAD0-7A847BF26BE5Q34358206-9CDF5C4C-232E-4DD2-A3FB-67AC648D1FD5Q34437852-3747C542-7B46-4D5A-8639-18E3D2994F10Q34718609-A36F2CF0-0FB9-4A7C-B16C-D97856B1F5A1Q34743297-CC771B77-AA0E-478F-BA0E-5ECB5BED11FBQ34744239-73C2E1F7-1812-42E3-9C34-09F030E3B926Q34847990-478FE5D3-6582-471E-8921-A61471276843Q34933694-9E745B6D-0346-463A-8693-4A5A8DF72583Q34934867-8759EC9F-6AC5-45BE-A1E1-8F47EF759EC7Q34941564-085D5659-8F2A-4636-B382-0444308DB377Q34993838-5BA91981-358B-4C14-B620-1A786746F27AQ35011950-9B747D47-F891-4498-9846-8A98E9C65930
P2860
Adjuvants for human vaccines--current status, problems and future prospects.
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Adjuvants for human vaccines--current status, problems and future prospects.
@ast
Adjuvants for human vaccines--current status, problems and future prospects.
@en
Adjuvants for human vaccines--current status, problems and future prospects.
@nl
type
label
Adjuvants for human vaccines--current status, problems and future prospects.
@ast
Adjuvants for human vaccines--current status, problems and future prospects.
@en
Adjuvants for human vaccines--current status, problems and future prospects.
@nl
prefLabel
Adjuvants for human vaccines--current status, problems and future prospects.
@ast
Adjuvants for human vaccines--current status, problems and future prospects.
@en
Adjuvants for human vaccines--current status, problems and future prospects.
@nl
P1433
P1476
Adjuvants for human vaccines--current status, problems and future prospects.
@en
P2093
P304
P356
10.1016/0264-410X(95)00011-O
P407
P577
1995-10-01T00:00:00Z